cgp 42112a has been researched along with avapro in 1 studies
| Studies (cgp 42112a) | Trials (cgp 42112a) | Recent Studies (post-2010) (cgp 42112a) | Studies (avapro) | Trials (avapro) | Recent Studies (post-2010) (avapro) |
|---|---|---|---|---|---|
| 233 | 0 | 35 | 1,369 | 385 | 495 |
| Protein | Taxonomy | cgp 42112a (IC50) | avapro (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.3067 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0099 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ager, EI; Chan, J; Chong, WW; Christophi, C; Neo, JH; Wen, SW | 1 |
1 other study(ies) available for cgp 42112a and avapro
| Article | Year |
|---|---|
Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.
Topics: Adenocarcinoma; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers, Tumor; Biphenyl Compounds; Captopril; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Irbesartan; Liver Neoplasms, Experimental; Mice; Mice, Inbred CBA; Molecular Targeted Therapy; Neoplasm Proteins; Neovascularization, Pathologic; Oligopeptides; Peptide Fragments; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Tetrazoles; Tumor Burden; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |